In this webinar, we will:
- Introduce and discuss the serotonin transporter SLC6A4 and the HTTPLR variant
- Highlight the clinical utility of SLC6A4 pharmacogenomic testing when prescribing antidepressants to treat major depressive disorder
- Introduce the new RightMed psychiatry report and feature a hypothetical case study
About the presenter
Ryan Gregg, Ph.D. is the Medical Science Liaison for the NE and SE U.S. at OneOme. He obtained a B.S. with Honors in Forensic Chemistry from the University of Mississippi, and a Ph.D. in Pharmacology from the Center for Substance Abuse and Research at Temple University School of Medicine. Ryan's background includes pre-clinical and clinical research in psychiatry and substance use disorders, including novel pre-clinical pharmacotherapy development targeting the serotonin transporter. He is passionate about both the pharmacokinetic and pharmacodynamic side of pharmacogenomics, especially in the research underlying the clinical impact of SLC6A4.